Total submissions: 2
Submitter | RCV | SCV | Clinical significance | Condition | Last evaluated | Review status | Method | Comment |
---|---|---|---|---|---|---|---|---|
Labcorp Genetics |
RCV001870200 | SCV002127194 | uncertain significance | Erythrocytosis, familial, 3 | 2023-05-27 | criteria provided, single submitter | clinical testing | In summary, the available evidence is currently insufficient to determine the role of this variant in disease. Therefore, it has been classified as a Variant of Uncertain Significance. An algorithm developed to predict the effect of missense changes on protein structure and function (PolyPhen-2) suggests that this variant is likely to be disruptive. ClinVar contains an entry for this variant (Variation ID: 1356650). This variant has not been reported in the literature in individuals affected with EGLN1-related conditions. This variant is present in population databases (rs748814440, gnomAD 0.006%). This sequence change replaces arginine, which is basic and polar, with cysteine, which is neutral and slightly polar, at codon 312 of the EGLN1 protein (p.Arg312Cys). |
Ambry Genetics | RCV004039592 | SCV002686346 | uncertain significance | not specified | 2023-03-30 | criteria provided, single submitter | clinical testing | The p.R312C variant (also known as c.934C>T), located in coding exon 2 of the EGLN1 gene, results from a C to T substitution at nucleotide position 934. The arginine at codon 312 is replaced by cysteine, an amino acid with highly dissimilar properties. This amino acid position is highly conserved in available vertebrate species. In addition, the in silico prediction for this alteration is inconclusive. Since supporting evidence is limited at this time, the clinical significance of this alteration remains unclear. |